Trial Profile
A retrospective, multicentre study evaluating efficacy and safety of sunitinib on Chinese patients with locally unresectable or metastatic Alveolar soft part sarcoma (ASPS).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Alveolar soft part sarcoma
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2016 New trial record
- 08 Sep 2016 Results published in the Investigational New Drugs